Microsoft and GlaxoSmithKline among companies involved in Viant blockchain programme
Ethereum blockchain-based supply chain platform, Viant, has teamed up with pharma giant GlaxoSmithKline and a number of other blue-chip organisations to accelerate the pace of blockchain-based supply chain systems within various industries.
The organisation’s platform leverages cryptographic security, and smart contracts to provide organisations insights as assets are managed and propagated throughout their entire supply chain.
The other companies confirmed as for the initiative are Microsoft, World Wide Fund for Nature, Imaginea, and an unnamed oil and gas super-major.
Over the past quarter, these companies have been modelling processes and assets on Viant to improve transparency, better comply with regulations, and unlock business value.
The programme was designed to enable the world's leading innovators to rapidly model and realise the most compelling blockchain use-cases on the platform, with each participant provided with a dedicated instance of the platform deployed on Microsoft Azure, managed by the Viant team.
Participants were on-boarded to the program with a kick off to ideate use cases, provide basic guidance on modelling and building with the tool. Through the beta programme, the participants collaborated with the Viant team to identify and prioritise feature requests to further their blockchain use cases.
“We experienced overwhelming demand to participate in the first cohort of the Beta program and our customers have responded with unbelievable enthusiasm after using the Viant platform,” said Tyler Mulvihill, Co-Founder and Global Business Development, Viant.
“We look forward to advancing these use cases to pilot and production systems and getting closer to a self-organising world.”